Authors: Taihua Wang, Xiaohui Cui, Zhenzhen Yang, Rongrong Li, Xinyi Shi, Linyu Cui, Mengqian Wang, Ning Zuo, Xiaojuan Diao, Kun Li, Limin Zhang, Guoke Yang, Ying Meng, Shuangshuang Cai, Ying Sun, Gang Zhang
Transplantation of directly-generated human pluripotent stem cells (dgHPSCs) overexpressing human insulin (INS) and/or estrogen-related receptor γ (ERRγ) genes can efficiently improve the symptoms of type 2 diabetes (T2D), such as the glucose (GLU) and glycosylated haemoglobin (HbA1c) levels, diabetes-derived complications, etc. Therefore, human stem cell transplantation might be a potential strategy to replace exogenous INS administration, and further to prevent the patients from developing diabetic complications. However, little is known concerning the efficacy duration of the transplanted stem cells. Here, we reported the following-up visits of one patient for a year. We found that the patient not only maintained almost normal blood glucose levels, but also his blood pressure decreased to normal range without taking anti-hypertensive drugs. Thus, our data indicated that the efficacy duration of transplanted stem cells can last about two years. At the same time, the transplanted stem cells can not only decrease the blood glucose levels, but also reduce the hypertensions in T2D patient.
View/Download pdf